FcγR dependent mechanisms of cytotoxic, agonistic, and neutralizing antibody activities

Trends in Immunology

Volumn 36, Issue 6, 2015, Pages 325-336

  Nimmerjahn, Falk ^a   Gordan, Sina ^a   Lux, Anja ^a  

^a UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

Author keywords

Agonistic antibody; Cytotoxicity; Fc receptor; Immunoglobulin G; Neutralizing antibody

Indexed keywords

CYTOTOXIC ANTIBODY; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4 ANTIBODY; FC RECEPTOR; HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY; IMMUNOGLOBULIN G; NEUTRALIZING ANTIBODY;

CLINICAL TRIAL (TOPIC); DRUG CYTOTOXICITY; DRUG MECHANISM; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOTHERAPY; INFLUENZA; NONHUMAN; PROTEIN EXPRESSION; REGULATORY T LYMPHOCYTE; REVIEW; T CELL DEPLETION; ANIMAL; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; BIOLOGICAL MODEL; COMMUNICABLE DISEASE; IMMUNOLOGY; INFLAMMATION;

ANIMALS; ANTIBODIES, NEUTRALIZING; ANTIBODY-DEPENDENT CELL CYTOTOXICITY; COMMUNICABLE DISEASES; HUMANS; IMMUNOGLOBULIN G; INFLAMMATION; MODELS, IMMUNOLOGICAL; RECEPTORS, IGG; T-LYMPHOCYTES, REGULATORY;

EID: 84930822871     PISSN: 14714906     EISSN: 14714981     Source Type: Journal    
DOI: 10.1016/j.it.2015.04.005     Document Type: Review

References (126)

1. Lim S.H., et al. Anti-CD20 monoclonal antibodies: historical and future perspectives. Haematologica 2010, 95:135-143.
2. Reichert J.M., et al. Monoclonal antibody successes in the clinic. Nat. Biotechnol. 2005, 23:1073-1078.
3. Nimmerjahn F., Ravetch J.V. Antibodies, Fc receptors and cancer. Curr. Opin. Immunol. 2007, 19:239-245.
4. French R.R., et al. CD40 antibody evokes a cytotoxic T-cell response that eradicates lymphoma and bypasses T-cell help. Nat. Med. 1999, 5:548-553.
5. White A.L., et al. FcgammaRIotaIotaB controls the potency of agonistic anti-TNFR mAbs. Cancer Immunol. Immunother. 2013, 62:941-948.
6. Pincetic A., et al. Type I and type II Fc receptors regulate innate and adaptive immunity. Nat. Immunol. 2014, 15:707-716.
7. Pappas L., et al. Rapid development of broadly influenza neutralizing antibodies through redundant mutations. Nature 2014, 516:418-422.
8. Walker L.M., et al. Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target. Science 2009, 326:285-289.
9. Scheid J.F., et al. Sequence and structural convergence of broad and potent HIV antibodies that mimic CD4 binding. Science 2011, 333:1633-1637.
10. Corti D., et al. Cross-neutralization of four paramyxoviruses by a human monoclonal antibody. Nature 2013, 501:4394-4443.
11. Bayry J., et al. Intravenous immunoglobulin therapy in rheumatic diseases. Nat. Rev. Rheumatol. 2011, 7:349-359.
12. Schwab I., Nimmerjahn F. Intravenous immunoglobulin therapy: how does IgG modulate the immune system?. Nat. Rev. Immunol. 2013, 13:176-189.
13. Nimmerjahn F., Ravetch J.V. Fc gamma receptors as regulators of immune responses. Nat. Rev. Immunol. 2008, 8:34-47.
14. Hogarth P.M., Pietersz G.A. Fc receptor-targeted therapies for the treatment of inflammation, cancer and beyond. Nat. Rev. Drug Discov. 2012, 11:311-331.
15. Daeron M., Lesourne R. Negative signaling in Fc receptor complexes. Adv. Immunol. 2006, 89:39-86.
16. Smith K.G., Clatworthy M.R. FcgammaRIIB in autoimmunity and infection: evolutionary and therapeutic implications. Nat. Rev. Immunol. 2010, 10:328-343.
17. Dutertre C.A., et al. A novel subset of NK cells expressing high levels of inhibitory FcgammaRIIB modulating antibody-dependent function. J. Leukoc. Biol. 2008, 84:1511-1520.
18. Biburger M., et al. Monocyte subsets responsible for immunoglobulin G-dependent effector functions in vivo. Immunity 2011, 35:932-944.
19. Starbeck-Miller G.R., et al. Cutting edge: expression of FcgammaRIIB tempers memory CD8 T cell function in vivo. J. Immunol. 2014, 192:35-39.
20. Bolland S., Ravetch J.V. Spontaneous autoimmune disease in Fc(gamma)RIIB-deficient mice results from strain-specific epistasis. Immunity 2000, 13:277-285.
21. Boross P., et al. The inhibiting Fc receptor for IgG, FcgammaRIIB, is a modifier of autoimmune susceptibility. J. Immunol. 2011, 187:1304-1313.
22. Clatworthy M.R., et al. Systemic lupus erythematosus-associated defects in the inhibitory receptor FcgammaRIIb reduce susceptibility to malaria. Proc. Natl. Acad. Sci. U.S.A. 2007, 104:7169-7174.
23. Floto R.A., et al. Loss of function of a lupus-associated FcgammaRIIb polymorphism through exclusion from lipid rafts. Nat. Med. 2005, 11:1056-1058.
24. Fukuyama H., et al. The inhibitory Fcgamma receptor modulates autoimmunity by limiting the accumulation of immunoglobulin G+ anti-DNA plasma cells. Nat. Immunol. 2005, 6:99-106.
25. Nimmerjahn F., Ravetch J.V. Antibody-mediated modulation of immune responses. Immunol. Rev. 2010, 236:265-275.
26. Biburger M., et al. How immunoglobulin G antibodies kill target cells: revisiting an old paradigm. Adv. Immunol. 2014, 124:67-94.
27. Clynes R., Ravetch J.V. Cytotoxic antibodies trigger inflammation through Fc receptors. Immunity 1995, 3:21-26.
28. Clynes R., et al. Fc receptors are required in passive and active immunity to melanoma. Proc. Natl. Acad. Sci. U.S.A. 1998, 95:652-656.
29. Takai T., et al. FcR gamma chain deletion results in pleiotrophic effector cell defects. Cell 1994, 76:519-529.
30. Hamaguchi Y., et al. Antibody isotype-specific engagement of Fc gamma receptors regulates B lymphocyte depletion during CD20 immunotherapy. J. Exp. Med. 2006, 203:743-753.
31. Beers S.A., et al. Antigenic modulation limits the efficacy of anti-CD20 antibodies: implications for antibody selection. Blood 2010, 115:5191-5201.
32. Pallasch C.P., et al. Sensitizing protective tumor microenvironments to antibody-mediated therapy. Cell 2014, 156:590-602.
33. Nimmerjahn F., Ravetch J.V. Divergent immunoglobulin g subclass activity through selective Fc receptor binding. Science 2005, 310:1510-1512.
34. Racila E., et al. A polymorphism in the complement component C1qA correlates with prolonged response following rituximab therapy of follicular lymphoma. Clin. Cancer Res. 2008, 14:6697-6703.
35. Wang S.Y., et al. NK-cell activation and antibody-dependent cellular cytotoxicity induced by rituximab-coated target cells is inhibited by the C3b component of complement. Blood 2008, 111:1456-1463.
36. Wang S.Y., et al. Depletion of the C3 component of complement enhances the ability of rituximab-coated target cells to activate human NK cells and improves the efficacy of monoclonal antibody therapy in an in vivo model. Blood 2009, 114:5322-5330.
37. Cartron G., et al. Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene. Blood 2002, 99:754-758.
38. Musolino A., et al. Immunoglobulin G fragment C receptor polymorphisms and clinical efficacy of trastuzumab-based therapy in patients with HER-2/neu-positive metastatic breast cancer. J. Clin. Oncol. 2008, 26:1789-1796.
39. Weng W.K., et al. Clinical outcome of lymphoma patients after idiotype vaccination is correlated with humoral immune response and immunoglobulin G Fc receptor genotype. J. Clin. Oncol. 2004, 22:4717-4724.
40. Weng W.K., Levy R. Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma. J. Clin. Oncol. 2003, 21:3940-3947.
41. Lux A., et al. A humanized mouse identifies the bone marrow as a niche with low therapeutic IgG activity. Cell Rep. 2014, 7:236-248.
42. Gul N., et al. Macrophages eliminate circulating tumor cells after monoclonal antibody therapy. J. Clin. Invest. 2014, 124:812-823.
43. Montalvao F., et al. The mechanism of anti-CD20-mediated B cell depletion revealed by intravital imaging. J. Clin. Invest. 2013, 123:5098-5103.
44. Uchida J., et al. The innate mononuclear phagocyte network depletes B lymphocytes through Fc receptor-dependent mechanisms during anti-CD20 antibody immunotherapy. J. Exp. Med. 2004, 199:1659-1669.
45. Clynes R.A., et al. Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets. Nat. Med. 2000, 6:443-446.
46. Takai T., et al. Augmented humoral and anaphylactic responses in Fc gamma RII-deficient mice. Nature 1996, 379:346-349.
47. de Haij S., et al. In vivo cytotoxicity of type I CD20 antibodies critically depends on Fc receptor ITAM signaling. Cancer Res. 2010, 70:3209-3217.
48. Simpson T.R., et al. Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti-CTLA-4 therapy against melanoma. J. Exp. Med. 2013, 210:1695-1710.
49. Furness A.J., et al. Impact of tumour microenvironment and Fc receptors on the activity of immunomodulatory antibodies. Trends Immunol. 2014, 35:290-298.
50. Quezada S.A., et al. CTLA4 blockade and GM-CSF combination immunotherapy alters the intratumor balance of effector and regulatory T cells. J. Clin. Invest. 2006, 116:1935-1945.
51. Schmidt E.M., et al. Ctla-4 controls regulatory T cell peripheral homeostasis and is required for suppression of pancreatic islet autoimmunity. J. Immunol. 2009, 182:274-282.
52. Hodi F.S., et al. Improved survival with ipilimumab in patients with metastatic melanoma. N. Engl. J. Med. 2010, 363:711-723.
53. Robert C., et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N. Engl. J. Med. 2011, 364:2517-2526.
54. Nimmerjahn F., et al. FcgammaRIV deletion reveals its central role for IgG2a and IgG2b activity in vivo. Proc. Natl. Acad. Sci. U.S.A. 2010, 107:19396-19401.
55. Otten M.A., et al. Experimental antibody therapy of liver metastases reveals functional redundancy between Fc gammaRI and Fc gammaRIV. J. Immunol. 2008, 181:6829-6836.
56. Selby M.J., et al. Anti-CTLA-4 antibodies of IgG2a isotype enhance antitumor activity through reduction of intratumoral regulatory T cells. Cancer Immunol. Res. 2013, 1:32-42.
57. Read S., et al. Blockade of CTLA-4 on CD4+CD25+ regulatory T cells abrogates their function in vivo. J. Immunol. 2006, 177:4376-4383.
58. Lux A., Nimmerjahn F. Of mice and men: the need for humanized mouse models to study human IgG activity in vivo. J. Clin. Immunol. 2013, 33(Suppl. 1):S4-S8.
59. Biburger M., Nimmerjahn F. Low level of FcgammaRIII expression on murine natural killer cells. Immunol. Lett. 2012, 143:53-59.
60. Herter S., et al. Preclinical activity of the type II CD20 antibody GA101 (obinutuzumab) compared with rituximab and ofatumumab in vitro and in xenograft models. Mol. Cancer Ther. 2013, 12:2031-2042.
61. Carter P.J. Potent antibody therapeutics by design. Nat. Rev. Immunol. 2006, 6:343-357.
62. Desjarlais J.R., Lazar G.A. Modulation of antibody effector function. Exp. Cell Res. 2011, 317:1278-1285.
63. Coiffier B., et al. Safety and efficacy of ofatumumab, a fully human monoclonal anti-CD20 antibody, in patients with relapsed or refractory B-cell chronic lymphocytic leukemia: a phase 1-2 study. Blood 2008, 111:1094-1100.
64. Taylor P.C., et al. Ofatumumab, a fully human anti-CD20 monoclonal antibody, in biological-naive, rheumatoid arthritis patients with an inadequate response to methotrexate: a randomised, double-blind, placebo-controlled clinical trial. Ann. Rheum. Dis. 2011, 70:2119-2125.
65. Haynes B.F., et al. Immune-correlates analysis of an HIV-1 vaccine efficacy trial. N. Engl. J. Med. 2012, 366:1275-1286.
66. Chung A.W., et al. Polyfunctional Fc-effector profiles mediated by IgG subclass selection distinguish RV144 and VAX003 vaccines. Sci. Transl. Med. 2014, 6:228ra38.
67. Klein F., et al. Antibodies in HIV-1 vaccine development and therapy. Science 2013, 341:1199-1204.
68. Shingai M., et al. Passive transfer of modest titers of potent and broadly neutralizing anti-HIV monoclonal antibodies block SHIV infection in macaques. J. Exp. Med. 2014, 211:2061-2074.
69. Barouch D.H., et al. Therapeutic efficacy of potent neutralizing HIV-1-specific monoclonal antibodies in SHIV-infected rhesus monkeys. Nature 2013, 503:224-228.
70. Kong R., et al. Improving Neutralization potency and breadth by combining broadly reactive HIV-1 antibodies targeting major neutralization epitopes. J. Virol. 2015, 89:2659-2671.
71. Horwitz J.A., et al. HIV-1 suppression and durable control by combining single broadly neutralizing antibodies and antiretroviral drugs in humanized mice. Proc. Natl. Acad. Sci. U.S.A. 2013, 110:16538-16543.
72. Shingai M., et al. Antibody-mediated immunotherapy of macaques chronically infected with SHIV suppresses viraemia. Nature 2013, 503:277-280.
73. Burton D.R., et al. Limited or no protection by weakly or nonneutralizing antibodies against vaginal SHIV challenge of macaques compared with a strongly neutralizing antibody. Proc. Natl. Acad. Sci. U.S.A. 2011, 108:11181-11186.
74. Verma A., et al. Analysis of the Fc gamma receptor-dependent component of neutralization measured by anthrax toxin neutralization assays. Clin. Vaccine Immunol. 2009, 16:1405-1412.
75. Forthal D.N., et al. Fc-glycosylation influences Fcgamma receptor binding and cell-mediated anti-HIV activity of monoclonal antibody 2G12. J. Immunol. 2010, 185:6876-6882.
76. Huber V.C., et al. Fc receptor-mediated phagocytosis makes a significant contribution to clearance of influenza virus infections. J. Immunol. 2001, 166:7381-7388.
77. Braster R., et al. Myeloid cells as effector cells for monoclonal antibody therapy of cancer. Methods 2013, 65:28-37.
78. Corti D., et al. A neutralizing antibody selected from plasma cells that binds to group 1 and group 2 influenza A hemagglutinins. Science 2011, 333:850-856.
79. DiLillo D.J., et al. Broadly neutralizing hemagglutinin stalk-specific antibodies require FcgR interactions for protectio against influenza virus in vivo. Nat. Med. 2014, 20:143-151.
80. Smith P., et al. Mouse model recapitulating human Fcgamma receptor structural and functional diversity. Proc. Natl. Acad. Sci. U.S.A. 2012, 109:6181-6186.
81. Jegaskanda S., et al. Cross-reactive influenza-specific antibody-dependent cellular cytotoxicity antibodies in the absence of neutralizing antibodies. J. Immunol. 2013, 190:1837-1848.
82. Jegaskanda S., et al. Antibody-dependent cellular cytotoxicity is associated with control of pandemic H1N1 influenza virus infection of macaques. J. Virol. 2013, 87:5512-5522.
83. Srivastava V., et al. Identification of dominant antibody-dependent cell-mediated cytotoxicity epitopes on the hemagglutinin antigen of pandemic H1N1 influenza virus. J. Virol. 2013, 87:5831-5840.
84. Corti D., Lanzavecchia A. Broadly neutralizing antiviral antibodies. Annu. Rev. Immunol. 2013, 31:705-742.
85. Mascola J.R. Passive transfer studies to elucidate the role of antibody-mediated protection against HIV-1. Vaccine 2002, 20:1922-1925.
86. Veazey R.S., et al. Prevention of virus transmission to macaque monkeys by a vaginally applied monoclonal antibody to HIV-1 gp120. Nat. Med. 2003, 9:343-346.
87. Walker L.M., Burton D.R. Rational antibody-based HIV-1 vaccine design: current approaches and future directions. Curr. Opin. Immunol. 2010, 22:358-366.
88. Pejchal R., et al. A potent and broad neutralizing antibody recognizes and penetrates the HIV glycan shield. Science 2011, 334:1097-1103.
89. Walker L.M., et al. Rapid development of glycan-specific, broad, and potent anti-HIV-1 gp120 neutralizing antibodies in an R5 SIV/HIV chimeric virus infected macaque. Proc. Natl. Acad. Sci. U.S.A. 2011, 108:20125-20129.
90. Hessell A.J., et al. Fc receptor but not complement binding is important in antibody protection against HIV. Nature 2007, 449:101-104.
91. Moldt B., et al. A nonfucosylated variant of the anti-HIV-1 monoclonal antibody b12 has enhanced FcgammaRIIIa-mediated antiviral activity in vitro but does not improve protection against mucosal SHIV challenge in macaques. J. Virol. 2012, 86:6189-6196.
92. Klein F., et al. HIV therapy by a combination of broadly neutralizing antibodies in humanized mice. Nature 2012, 492:118-122.
93. Klein F., et al. Enhanced HIV-1 immunotherapy by commonly arising antibodies that target virus escape variants. J. Exp. Med. 2014, 211:2361-2372.
94. Mascola J.R., et al. Protection of macaques against vaginal transmission of a pathogenic HIV-1/SIV chimeric virus by passive infusion of neutralizing antibodies. Nat. Med. 2000, 6:207-210.
95. Halper-Stromberg A., et al. Broadly neutralizing antibodies and viral inducers decrease rebound from HIV-1 latent reservoirs in humanized mice. Cell 2014, 158:989-999.
96. Bournazos S., et al. Human IgG Fc domain engineering enhances antitoxin neutralizing antibody activity. J. Clin. Invest. 2014, 124:725-729.
97. Gomez-Roman V.R., et al. Vaccine-elicited antibodies mediate antibody-dependent cellular cytotoxicity correlated with significantly reduced acute viremia in rhesus macaques challenged with SIVmac251. J. Immunol. 2005, 174:2185-2189.
98. Florese R.H., et al. Evaluation of passively transferred, nonneutralizing antibody-dependent cellular cytotoxicity-mediating IgG in protection of neonatal rhesus macaques against oral SIVmac251 challenge. J. Immunol. 2006, 177:4028-4036.
99. Forthal D.N., Moog C. Fc receptor-mediated antiviral antibodies. Curr. Opin. HIV AIDS 2009, 4:388-393.
100. Ko S.Y., et al. Enhanced neonatal Fc receptor function improves protection against primate SHIV infection. Nature 2014, 514:642-645.
101. Abboud N., et al. A requirement for FcgammaR in antibody-mediated bacterial toxin neutralization. J. Exp. Med. 2010, 207:2395-2405.
102. Suntharalingam G., et al. Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412. N. Engl. J. Med. 2006, 355:1018-1028.
103. Vonderheide R.H. Prospect of targeting the CD40 pathway for cancer therapy. Clin. Cancer Res. 2007, 13:1083-1088.
104. Ichikawa K., et al. Tumoricidal activity of a novel anti-human DR5 monoclonal antibody without hepatocyte cytotoxicity. Nat. Med. 2001, 7:954-960.
105. Natoni A., et al. TRAIL signals to apoptosis in chronic lymphocytic leukaemia cells primarily through TRAIL-R1 whereas cross-linked agonistic TRAIL-R2 antibodies facilitate signalling via TRAIL-R2. Br. J. Haematol. 2007, 139:568-577.
106. Xu Y., et al. Fc gamma Rs modulate cytotoxicity of anti-Fas antibodies: implications for agonistic antibody-based therapeutics. J. Immunol. 2003, 171:562-568.
107. White A.L., et al. Fcgamma receptor dependency of agonistic CD40 antibody in lymphoma therapy can be overcome through antibody multimerization. J. Immunol. 2014, 193:1828-1835.
108. Li F., Ravetch J.V. Antitumor activities of agonistic anti-TNFR antibodies require differential FcgammaRIIB coengagement in vivo. Proc. Natl. Acad. Sci. U.S.A. 2013, 110:19501-19506.
109. Ganesan L.P., et al. FcgammaRIIb on liver sinusoidal endothelium clears small immune complexes. J. Immunol. 2012, 189:4981-4988.
110. Wilson N.S., et al. An Fcgamma receptor-dependent mechanism drives antibody-mediated target-receptor signaling in cancer cells. Cancer Cell 2011, 19:101-113.
111. Li F., Ravetch J.V. Inhibitory Fcgamma receptor engagement drives adjuvant and anti-tumor activities of agonistic CD40 antibodies. Science 2011, 333:1030-1034.
112. White A.L., et al. Interaction with FcgammaRIIB is critical for the agonistic activity of anti-CD40 monoclonal antibody. J. Immunol. 2011, 187:1754-1763.
113. Ravetch J.V., Nimmerjahn F. Fc receptors. Fundamental Immunology 2008, 684-705. Lippincott-Raven. W.E. Paul (Ed.).
114. Dudziak D., et al. Differential antigen processing by dendritic cell subsets in vivo. Science 2007, 315:107-111.
115. Bartholomaeus P., et al. Cell contact-dependent priming and Fc interaction with CD32+ immune cells contribute to the TGN1412-triggered cytokine response. J. Immunol. 2014, 192:2091-2098.
116. Hussain K., et al. Upregulation of FcgammaRIIb on monocytes is necessary to promote the superagonist activity of TGN1412. Blood 2015, 125:102-110.
117. Bruhns P., et al. Specificity and affinity of human Fcgamma receptors and their polymorphic variants for human IgG subclasses. Blood 2009, 113:3716-3725.
118. Li F., Ravetch J.V. Apoptotic and antitumor activity of death receptor antibodies require inhibitory Fcgamma receptor engagement. Proc. Natl. Acad. Sci. U.S.A. 2012, 109:10966-10971.
119. Nimmerjahn F., et al. FcgammaRIV: a novel FcR with distinct IgG subclass specificity. Immunity 2005, 23:41-51.
120. Guyre P.M., et al. Recombinant immune interferon increases immunoglobulin G Fc receptors on cultured human mononuclear phagocytes. J. Clin. Invest. 1983, 72:393-397.
121. Shushakova N., et al. C5a anaphylatoxin is a major regulator of activating versus inhibitory FcgammaRs in immune complex-induced lung disease. J. Clin. Invest. 2002, 110:1823-1830.
122. Okayama Y., et al. Expression of a functional high-affinity IgG receptor, Fc gamma RI, on human mast cells: Up-regulation by IFN-gamma. J. Immunol. 2000, 164:4332-4339.
123. Pricop L., et al. Differential modulation of stimulatory and inhibitory Fc gamma receptors on human monocytes by Th1 and Th2 cytokines. J. Immunol. 2001, 166:531-537.
124. Tridandapani S., et al. TGF-beta 1 suppresses [correction of supresses] myeloid Fc gamma receptor function by regulating the expression and function of the common gamma-subunit. J. Immunol. 2003, 170:4572-4577.
125. White A.L., et al. Conformation of the human immunoglobulin g2 hinge imparts superagonistic properties to immunostimulatory anticancer antibodies. Cancer Cell 2015, 27:138-148.
126. Lux A., Nimmerjahn F. No need for constant help: human IgG2 antibodies have an autonomous agonistic activity for immunotherapy of cancer. Cancer Cell 2015, 27:10-11.